We are live on ! Find out more

InspireMD

NSPR

Market cap $24M

0.5126 USD

+0.0210

4.27%

At close Updated Oct 13, 2:28 PM EDT

1 day

4.27%

5 days

-4.19%

1 month

-36.67%

3 months

-28.71%

6 months

-62.03%

Year to date

-72.44%

1 year

-78.82%

5 years

-87.56%

10 years

-100%

About: InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

Employees: 127

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 11.1%

Neutral 88.9%

Negative 0%

InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million

- Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime 80 cm, which the Company continues to anticipate in Q4 2026 -

InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIAMI, Sept. 04, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to a new non-executive employee in the aggregate amount of 23,764 shares of restricted stock (the “Inducement Grants”) outside of InspireMD's 2021 Equity Incentive Plan, with a grant date as of September 2, 2026, as an inducement material to the non-executive employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference

MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming H.C.

InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference

Zacks Investment Research

InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know

InspireMD (NSPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know

InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript

InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript

InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript

InspireMD Reports Second Quarter 2026 Financial Results

- Company to host investor conference call today, August 17 th , at 8:30am EDT - MIAMI, Aug. 17, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the three and six months ended June 30, 2026. Recent Business Highlights: Generated revenue of $1.8 million in the second quarter of 2026, in line with the second quarter of 2025.

InspireMD Reports Second Quarter 2026 Financial Results

Zacks Investment Research

InspireMD, Inc. (NSPR) Reports Q2 Loss, Beats Revenue Estimates

InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.26 per share a year ago.

InspireMD, Inc. (NSPR) Reports Q2 Loss, Beats Revenue Estimates

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to a new non-executive employee in the aggregate amount of 221,666 shares of restricted stock (the “Inducement Grants”) outside of InspireMD's 2021 Equity Incentive Plan, with a grant date as of August 3, 2026, as an inducement material to the non-executive employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants were granted under the InspireMD's 2024 Inducement Plan, which is used exclusively for the grant of equity awards to individuals who were not previously employees of InspireMD, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with InspireMD, pursuant to Nasdaq Listing Rule 5635(c)(4).

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing

Ms. Kennedy returns to InspireMD having previously served as Sales Director supporting the initial U.S. launch of CGuard Prime Ms. Kennedy returns to InspireMD having previously served as Sales Director supporting the initial U.S. launch of CGuard Prime

InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing

Zacks Investment Research

InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR

NSPR's positive CGUARDIANS II data show 100% acute device success, supporting a potential FDA approval for CGuard Prime TCAR in late 2026.

InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR

See News Rankings

Price charts implemented using Lightweight Charts™